---
layout: default
title: Pegfilgrastim
parent: 僅模型預測 (L5)
nav_order: 761
evidence_level: L5
indication_count: 10
---

# Pegfilgrastim
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Pegfilgrastim: From Neutropenia (G-CSF Class) to Severe Nonproliferative Diabetic Retinopathy

## One-Sentence Summary

> Pegfilgrastim is a pegylated G-CSF (granulocyte colony-stimulating factor) analog; internationally it is used to stimulate neutrophil recovery, most commonly in the setting of chemotherapy-induced neutropenia (specific Singapore label text unavailable — drug is currently unmarketed here).
> The TxGNN model predicts it may be effective for **Severe Nonproliferative Diabetic Retinopathy**,
> but this direction is currently supported by **0 clinical trials** and **0 publications**, and the model's own rationale text flags no known mechanistic link.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not registered in Singapore (drug unmarketed); internationally used for chemotherapy-induced neutropenia (G-CSF class) |
| Predicted New Indication | Severe Nonproliferative Diabetic Retinopathy |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| Singapore Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in the source registry for this candidate (marked as a data gap). Based on the drug class information present in the evidence pack, Pegfilgrastim is a G-CSF analog whose primary pharmacology is stimulating proliferation and differentiation of bone marrow granulocyte precursors and mobilizing neutrophils into circulation.

Severe nonproliferative diabetic retinopathy is a microvascular disease driven by chronic hyperglycemia-induced capillary damage, ischemia, and (at more advanced stages) pathological neovascularization. The TxGNN model's own rationale text for this pairing states that there is **no direct known mechanistic link** between G-CSF-driven granulocyte mobilization and retinal microvascular/ischemic pathology — the only cited connection is a speculative and non-specific literature thread on G-CSF mobilizing endothelial progenitor cells in ischemic tissue repair generally, which does not specifically implicate retinal disease.

In short, the high TxGNN score for this pairing appears to reflect a graph-topology association rather than an established or even plausible biological mechanism. This should be treated as a hypothesis-generating signal only, not as evidence of therapeutic potential.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Singapore Market Information

Pegfilgrastim currently has no registered license records in the Singapore regulatory dataset provided (market status: Not Marketed, 0 registrations).

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction sits at evidence level L5 — a pure model-generated association with zero supporting clinical trials or literature, and the model's own rationale explicitly notes the absence of a credible mechanistic link between G-CSF pharmacology and diabetic retinopathy pathophysiology. Combined with missing MOA and safety/label data (including a blocking gap on TFDA/HSA warnings and contraindications) and the drug's unmarketed status in Singapore, there is currently no basis to advance this candidate beyond hypothesis stage.

**To proceed, the following is needed:**
- Confirmed mechanism-of-action data from DrugBank API (currently a data gap)
- TFDA/HSA package insert warnings and contraindications (blocking gap — required before any S1 safety screening)
- Preclinical or mechanistic studies specifically evaluating G-CSF/Pegfilgrastim in retinal microvascular or ischemic disease models, to establish biological plausibility before pursuing clinical evidence
- If pursued, a Singapore market-entry regulatory assessment, since the drug is not currently registered
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

